Literature DB >> 31558622

MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis.

Susan K Mathai1,2, Stephen Humphries3, Jonathan A Kropski4, Timothy S Blackwell4,5, Julia Powers6, Avram D Walts6, Cheryl Markin4, Julia Woodward6, Jonathan H Chung3,7, Kevin K Brown8, Mark P Steele6, James E Loyd4, Marvin I Schwarz6, Tasha Fingerlin9, Ivana V Yang6, David A Lynch3, David A Schwartz6.   

Abstract

BACKGROUND: Relatives of patients with familial interstitial pneumonia (FIP) are at increased risk for pulmonary fibrosis. We assessed the prevalence and risk factors for preclinical pulmonary fibrosis (PrePF) in first-degree relatives of patients with FIP and determined the utility of deep learning in detecting PrePF on CT.
METHODS: First-degree relatives of patients with FIP over 40 years of age who believed themselves to be unaffected by pulmonary fibrosis underwent CT scans of the chest. Images were visually reviewed, and a deep learning algorithm was used to quantify lung fibrosis. Genotyping for common idiopathic pulmonary fibrosis risk variants in MUC5B and TERT was performed.
FINDINGS: In 494 relatives of patients with FIP from 263 families of patients with FIP, the prevalence of PrePF on visual CT evaluation was 15.6% (95% CI 12.6 to 19.0). Compared with visual CT evaluation, deep learning quantitative CT analysis had 84% sensitivity (95% CI 0.72 to 0.89) and 86% sensitivity (95% CI 0.83 to 0.89) for discriminating subjects with visual PrePF diagnosis. Subjects with PrePF were older (65.9, SD 10.1 years) than subjects without fibrosis (55.8 SD 8.7 years), more likely to be male (49% vs 37%), more likely to have smoked (44% vs 27%) and more likely to have the MUC5B promoter variant rs35705950 (minor allele frequency 0.29 vs 0.21). MUC5B variant carriers had higher quantitative CT fibrosis scores (mean difference of 0.36%), a difference that remains significant when controlling for age and sex.
INTERPRETATION: PrePF is common in relatives of patients with FIP. Its prevalence increases with age and the presence of a common MUC5B promoter variant. Quantitative CT analysis can detect these imaging abnormalities. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; Imaging/CT MRI etc; Interstitial Fibrosis

Mesh:

Substances:

Year:  2019        PMID: 31558622      PMCID: PMC7535073          DOI: 10.1136/thoraxjnl-2018-212430

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  32 in total

1.  Interobserver variability in the CT assessment of honeycombing in the lungs.

Authors:  Takeyuki Watadani; Fumikazu Sakai; Takeshi Johkoh; Satoshi Noma; Masanori Akira; Kiminori Fujimoto; Alexander A Bankier; Kyung Soo Lee; Nestor L Müller; Jae-Woo Song; Jai-Soung Park; David A Lynch; David M Hansell; Martine Remy-Jardin; Tomás Franquet; Yukihiko Sugiyama
Journal:  Radiology       Date:  2012-12-06       Impact factor: 11.105

2.  Genetic epidemiology of COPD (COPDGene) study design.

Authors:  Elizabeth A Regan; John E Hokanson; James R Murphy; Barry Make; David A Lynch; Terri H Beaty; Douglas Curran-Everett; Edwin K Silverman; James D Crapo
Journal:  COPD       Date:  2010-02       Impact factor: 2.409

Review 3.  Validation of multidisciplinary diagnosis in IPF.

Authors:  Diego Castillo; Simon Walsh; David M Hansell; Martina Vasakova; Vincent Cottin; Goksel Altinisik; Stefano Palmucci; Martina Sterclova; Sergio Harari; Luca Richeldi; Carlo Vancheri; Athol U Wells
Journal:  Lancet Respir Med       Date:  2018-02       Impact factor: 30.700

4.  Interstitial lung diseases in a lung cancer screening trial.

Authors:  N Sverzellati; L Guerci; G Randi; E Calabrò; C La Vecchia; A Marchianò; A Pesci; M Zompatori; U Pastorino
Journal:  Eur Respir J       Date:  2011-01-13       Impact factor: 16.671

5.  Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis.

Authors:  Carmel J Stock; Hiroe Sato; Carmen Fonseca; Winston A S Banya; Philip L Molyneaux; Huzaifa Adamali; Anne-Marie Russell; Christopher P Denton; David J Abraham; David M Hansell; Andrew G Nicholson; Toby M Maher; Athol U Wells; Gisela E Lindahl; Elisabetta A Renzoni
Journal:  Thorax       Date:  2013-01-15       Impact factor: 9.139

6.  Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes.

Authors:  Rongrong Wei; Chong Li; Min Zhang; Yava L Jones-Hall; Jamie L Myers; Imre Noth; Wanqing Liu
Journal:  Transl Res       Date:  2013-12-17       Impact factor: 7.012

7.  Association Between Interstitial Lung Abnormalities and All-Cause Mortality.

Authors:  Rachel K Putman; Hiroto Hatabu; Tetsuro Araki; Gunnar Gudmundsson; Wei Gao; Mizuki Nishino; Yuka Okajima; Josée Dupuis; Jeanne C Latourelle; Michael H Cho; Souheil El-Chemaly; Harvey O Coxson; Bartolome R Celli; Isis E Fernandez; Oscar E Zazueta; James C Ross; Rola Harmouche; Raúl San José Estépar; Alejandro A Diaz; Sigurdur Sigurdsson; Elías F Gudmundsson; Gudny Eiríksdottír; Thor Aspelund; Matthew J Budoff; Gregory L Kinney; John E Hokanson; Michelle C Williams; John T Murchison; William MacNee; Udo Hoffmann; Christopher J O'Donnell; Lenore J Launer; Tamara B Harrris; Vilmundur Gudnason; Edwin K Silverman; George T O'Connor; George R Washko; Ivan O Rosas; Gary M Hunninghake
Journal:  JAMA       Date:  2016-02-16       Impact factor: 56.272

8.  Lung volumes and emphysema in smokers with interstitial lung abnormalities.

Authors:  George R Washko; Gary M Hunninghake; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; James C Ross; Raúl San José Estépar; David A Lynch; John M Brehm; Katherine P Andriole; Alejandro A Diaz; Ramin Khorasani; Katherine D'Aco; Frank C Sciurba; Edwin K Silverman; Hiroto Hatabu; Ivan O Rosas
Journal:  N Engl J Med       Date:  2011-03-10       Impact factor: 91.245

9.  A comparison of visual and quantitative methods to identify interstitial lung abnormalities.

Authors:  Corrine R Kliment; Tetsuro Araki; Tracy J Doyle; Wei Gao; Josée Dupuis; Jeanne C Latourelle; Oscar E Zazueta; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; James C Ross; Raúl San José Estépar; Alejandro A Diaz; David J Lederer; David A Schwartz; Edwin K Silverman; Ivan O Rosas; George R Washko; George T O'Connor; Hiroto Hatabu; Gary M Hunninghake
Journal:  BMC Pulm Med       Date:  2015-10-29       Impact factor: 3.317

Review 10.  Epidemiology of idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard
Journal:  Clin Epidemiol       Date:  2013-11-25       Impact factor: 4.790

View more
  16 in total

1.  Development and Progression of Radiologic Abnormalities in Individuals at Risk for Familial Interstitial Lung Disease.

Authors:  Margaret L Salisbury; Justin C Hewlett; Guixiao Ding; Cheryl R Markin; Katrina Douglas; Wendi Mason; Adam Guttentag; John A Phillips; Joy D Cogan; Sara Reiss; Daphne B Mitchell; Pingsheng Wu; Lisa R Young; Lisa H Lancaster; James E Loyd; Stephen M Humphries; David A Lynch; Jonathan A Kropski; Timothy S Blackwell
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

2.  Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society.

Authors:  Hiroto Hatabu; Gary M Hunninghake; Luca Richeldi; Kevin K Brown; Athol U Wells; Martine Remy-Jardin; Johny Verschakelen; Andrew G Nicholson; Mary B Beasley; David C Christiani; Raúl San José Estépar; Joon Beom Seo; Takeshi Johkoh; Nicola Sverzellati; Christopher J Ryerson; R Graham Barr; Jin Mo Goo; John H M Austin; Charles A Powell; Kyung Soo Lee; Yoshikazu Inoue; David A Lynch
Journal:  Lancet Respir Med       Date:  2020-07       Impact factor: 30.700

Review 3.  Contributions of alveolar epithelial cell quality control to pulmonary fibrosis.

Authors:  Jeremy Katzen; Michael F Beers
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

Review 4.  Familial Interstitial Lung Disease.

Authors:  Jonathan A Kropski
Journal:  Semin Respir Crit Care Med       Date:  2020-04-12       Impact factor: 3.119

5.  Pulmonary fibrosis screening: quantifying the psychological impact.

Authors:  Chad A Newton
Journal:  Thorax       Date:  2021-02-23       Impact factor: 9.139

6.  Preclinical Pulmonary Fibrosis Circulating Protein Biomarkers.

Authors:  Susan K Mathai; Jonathan Cardwell; Fabian Metzger; Julia Powers; Avram D Walts; Jonathan A Kropski; Oliver Eickelberg; Stefanie M Hauck; Ivana V Yang; David A Schwartz
Journal:  Am J Respir Crit Care Med       Date:  2020-12-15       Impact factor: 21.405

7.  Progress and Research Priorities in Imaging Genomics for Heart and Lung Disease: Summary of an NHLBI Workshop.

Authors:  Donna K Arnett; Ramachandran S Vasan; Matthew Nayor; Li Shen; Gary M Hunninghake; Peter Kochunov; R Graham Barr; David A Bluemke; Ulrich Broeckel; Peter Caravan; Susan Cheng; Paul S de Vries; Udo Hoffmann; Márton Kolossváry; Huiqing Li; James Luo; Elizabeth M McNally; George Thanassoulis
Journal:  Circ Cardiovasc Imaging       Date:  2021-08-13       Impact factor: 8.589

Review 8.  Clinical Relevance and Management of "Pre-Interstitial Lung Disease".

Authors:  Anna J Podolanczuk; Rachel K Putman
Journal:  Clin Chest Med       Date:  2021-06       Impact factor: 4.967

Review 9.  Familial Pulmonary Fibrosis: Genetic Features and Clinical Implications.

Authors:  David Zhang; Chad A Newton
Journal:  Chest       Date:  2021-06-26       Impact factor: 9.410

Review 10.  Interstitial Lung Abnormalities: State of the Art.

Authors:  Akinori Hata; Mark L Schiebler; David A Lynch; Hiroto Hatabu
Journal:  Radiology       Date:  2021-08-10       Impact factor: 29.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.